olivLaw · US equity research
DataMeds AI, Inc. MEDS
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122 · Vertical: Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
DataMeds AI, Inc. is a healthcare company that links a wholesale drug distributor, a pharmacy and a technology hub platform into what it calls a 'micro health ecosystem'. The company was renamed from Wellgistics Health in July 2026 and is operating under financial strain, with modest revenue and large operating losses in the second quarter of 2026.
At the close of 04 Nov 2026, DataMeds AI, Inc. (MEDS) stock was 1.49 USD (−17.22% on the day), with market capitalisation 4.6 m USD, beta 0.92, 52-week range 0.85–34.50 USD. Latest reported quarter (Q2 2026): revenue of 1.8 m USD (−77.2% YoY), net income of -18.4 m USD, diluted EPS -7.13 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 33.5
- weak (30–45)
- Bollinger (20, 2)
- 1.45 – 3.45
- in the lower half of the band · %B 0.02 · band width 81.6%
- SMA 50 / 200
- 2.49 / 5.59
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.31 / -0.20
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −55.5% | −1.1% | −54.4 pp | — |
| 3 months | −46.8% | −0.5% | −46.3 pp | — |
| 6 months | −68.0% | +4.4% | −72.3 pp | — |
| Year to date | −92.6% | +12.3% | −104.9 pp | — |
| 1 year | −95.3% | +13.5% | −108.9 pp | +8.1% |
| 3 years | unavailable | +76.4% | unavailable | +18.9% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.7 m | 12.4 m | 10.9 m | 7.8 m | 3.0 m | 1.7 m | 1.6 m | 1.8 m |
| Cost of revenue | 5.2 m | 11.2 m | 10.2 m | 7.3 m | 2.8 m | 9.5 m | 1.4 m | 1.6 m |
| Gross profit | 521.2 k | 1.2 m | 692.6 k | 505.8 k | 231.0 k | -7.9 m | 170.2 k | 182.2 k |
| Operating income | -1.7 m | -3.7 m | -31.3 m | -5.5 m | -31.5 m | -25.4 m | -6.0 m | -7.3 m |
| Depreciation & amortisation | 467.4 k | 647.2 k | 802.9 k | 802.8 k | 802.8 k | 802.6 k | 356.8 k | 356.6 k |
| Interest expense | 137.6 k | 689.2 k | 1.1 m | 1.2 m | 1.4 m | 875.7 k | 2.1 m | 1.6 m |
| Pre-tax income | -1.9 m | -4.3 m | -32.4 m | -6.7 m | -34.3 m | -27.9 m | -7.7 m | -18.4 m |
| Net income | -1.9 m | -4.3 m | -32.4 m | -6.7 m | -34.3 m | -27.9 m | -7.7 m | -18.4 m |
| Diluted EPS | -0.04 | -0.09 ≈ | -0.62 | -5.40 | -0.46 | -0.29 ≈ | -0.07 | -7.13 |
| Operating cash flow | 1.0 m ≈ | -2.6 m | -1.3 m | -2.1 m ≈ | -1.1 m ≈ | -6.3 m | -3.4 m | -2.9 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | 18.1 m | 23.3 m |
| Revenue YoY | unavailable | unavailable | +28.7% |
| Net income | -2.9 m | -6.9 m | -101.3 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -0.06 | -0.15 | -1.43 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | -37.8% | -433.9% |
| Free cash flow | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 42.6 k USD
- Financial debt
- 23.5 m USD
- Net debt
- 23.4 m USD
- Equity
- -12.4 m USD
- Total assets
- 30.5 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.09x
- ROE
- unavailable
- ROA
- -230.7%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | — | 18.1 m | 23.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Cost of revenue | — | 16.4 m | 29.8 m | SEC (XBRL)· 20 Mar 2026verified |
| Gross profit | — | 1.8 m | -6.4 m | SEC (XBRL)· 20 Mar 2026verified |
| Operating income | -2.9 m | -6.1 m | -93.7 m | SEC (XBRL)· 20 Mar 2026verified |
| Depreciation & amortisation | — | 1.1 m | 3.2 m | SEC (XBRL)· 20 Mar 2026verified |
| EBITDA | — | -5.0 m ≈ | -90.5 m ≈ | SEC (XBRL)· 20 Mar 2026derived |
| Interest expense | 15.1 k | 831.5 k | 4.6 m | SEC (XBRL)· 20 Mar 2026verified |
| Pre-tax income | -2.9 m | -6.9 m | -101.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Net income | -2.9 m | -6.9 m | -101.3 m | SEC (XBRL)· 20 Mar 2026verified |
| Diluted EPS | -0.06 | -0.15 | -1.43 | SEC (XBRL)· 20 Mar 2026verified |
| Weighted average diluted shares | 44.7 m | 47.3 m | 71.0 m | SEC (XBRL)· 20 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 1.4 k | 1.0 m | 42.6 k | SEC (XBRL)· 20 Mar 2026verified |
| Receivables | — | — | 1.1 m | SEC (XBRL)· 19 May 2026verified |
| Inventories | — | 9.5 m | 1.6 m | SEC (XBRL)· 20 Mar 2026verified |
| Current assets | 338.4 k | 15.2 m | 2.8 m | SEC (XBRL)· 20 Mar 2026verified |
| Property, plant & equipment, net | — | 388.2 k | 229.4 k | SEC (XBRL)· 20 Mar 2026verified |
| Goodwill | — | 16.2 m | 14.2 m | SEC (XBRL)· 20 Mar 2026verified |
| Intangibles (excl. goodwill) | — | 1.6 m | 2.5 m | SEC (XBRL)· 20 Mar 2026verified |
| Total assets | 338.4 k | 57.3 m | 30.5 m | SEC (XBRL)· 20 Mar 2026verified |
| Short-term debt | 350.0 k | 11.9 m | 10.9 m | SEC (XBRL)· 20 Mar 2026verified |
| Long-term debt | — | 11.5 m | 12.6 m | SEC (XBRL)· 20 Mar 2026verified |
| Current liabilities | 2.9 m | 38.0 m | 29.8 m | SEC (XBRL)· 20 Mar 2026verified |
| Total liabilities | 3.2 m | 50.6 m | 42.9 m | SEC (XBRL)· 20 Mar 2026verified |
| Equity | -2.9 m † | 6.7 m † | -12.4 m † | SEC (XBRL)· 20 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -349.1 k | -1.2 m | -10.9 m | SEC (XBRL)· 20 Mar 2026verified |
| Investing cash flow | — | 469.1 k | -881.5 k | SEC (XBRL)· 20 Mar 2026verified |
| Financing cash flow | 350.5 k | 1.8 m | 10.8 m | SEC (XBRL)· 20 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 16.7% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 4.6 m USD
Key indicators
Coverage and freshness
Score by group
17% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -1,100.3% | 0 (vs peers) | 38% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -11.8x | 0 (on a fixed band) | 38% |
| Current ratio · Balance sheet | 0.1x | 0 (on a fixed band) | 25% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
DataMeds AI, Inc. (MEDS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 23.3 m USD in 2025; YoY growth 28.7%; net margin -1,100.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Net margin: -1,100.3%
- Interest coverage: -11.8x
- Current ratio: 0.1x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MCKMcKESSON CORPORATION | 123.5 bn | 27.5 | — | 1.1% | +12.4% | +21% / +127% |
| CORCencora, Inc. | 67.6 bn | 26.3 | 104.3% | 0.8% | +9.3% | −4% / +74% |
| CAHCardinal Health, Inc. | 60.9 bn | 36.2 | — | 0.7% | +14.2% | +23% / +145% |
| HLFHerbalife Ltd. | 1.6 bn | 9.1 | — | 3.4% | +0.9% | +20% / +19% |
| NUSNu Skin Enterprises, Inc. | 242.9 m | — | -32.5% | -15.7% | −14.3% | −50% / −71% |
| COSMCosmos Health Inc. | 33.0 m | — | -104.0% | -33.1% | +19.9% | −49% / −69% |
| HKPDCellyan Biotechnology Co., Ltd | 30.2 m | — | -0.6% | -0.1% | +21.7% | +87% / unavailable |
| ESYNHwh International Inc. | 11.6 m | — | -88.9% | -680.0% | −30.8% | −4% / −97% |
| MEDSDataMeds AI, Inc. | 4.6 m | — | — | -1,100.3% | +28.7% | −95% / unavailable |
1- and 3-year price returns: for MEDS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
DataMeds AI, Inc. is a healthcare company that links a wholesale drug distributor, a pharmacy and a technology hub platform into what it calls a 'micro health ecosystem'. The company was renamed from Wellgistics Health in July 2026 and is operating under financial strain, with modest revenue and large operating losses in the second quarter of 2026 23.
SWOT
Strengths
- The company has a distribution network serving independent pharmacies and a federal distributor licence, giving access to a large base of customers.
- Its integrated portfolio, from distribution to pharmacy to technology platform, allows a coordinated offer to patients and manufacturers.
- The company beat its management revenue projections in the second quarter of 2026.
Weaknesses
- Operating losses are large relative to revenue, and the company depends on new funding and debt restructuring.
- The operating history is short, and many of the services described are still in development.
- Near-term debt maturities and convertible notes put pressure on liquidity.
Opportunities
- If the patient app and manufacturer partnerships develop, the company could build recurring revenue from SaaS services.
- The specialty lite market and interest in digital care could open new revenue channels.
- Closing the proposed transaction could consolidate intellectual property in healthcare data.
Threats
- Pressure on reimbursement and pharmacy margins could reduce the profitability of distribution and pharmacy activities.
- The risk of Nasdaq delisting and lock-up restrictions could affect share liquidity.
- Data privacy and cybersecurity rules raise compliance costs and the risk of penalties.
Risks
- Liquidity and debthigh
The company reported large operating losses and depends on new financing and restructurings, which could limit its ability to sustain operations.
- Delisting riskhigh
According to the release, the company carried out a reverse split partly to address Nasdaq delisting risk, and continued listing remains uncertain.
- Dependence on the Datavault transactionmedium
Much of the planned strategy depends on closing the proposed transaction, which still awaits approvals and could delay the company's plans.
- Reimbursement and marginsmedium
Lower reimbursement or changes in pricing benchmarks could affect the results of the pharmacy and distributor.
- Regulation and privacylow
Data protection laws and regulatory requirements for pharmacies and medical services could raise costs and litigation exposure.
Investment thesis
What would need to be true (bull case)
- If revenue keeps growing after the second quarter of 2026, the company could show that its integrated model works in practice 3.
- Solid partnerships with a network of independent pharmacies and manufacturers could produce a more stable revenue stream.
- A successful launch of the patient app and related services could open a new market in medical data and treatment adherence.
What would break the thesis
- Large operating losses and the need for new funding could force further dilution or costly restructurings.
- If the proposed transaction does not close, a significant part of the company's strategy could remain unrealised.
- Delisting risk and restrictions on existing shares could reduce liquidity and investor confidence.
What to watch
- Launch of the Health Lives Here app together with NFL Alumni HealthQ3 2026
- Closing of the transaction with Datavault AI and its partnerssecond half 2026
- Trend in revenue and operating loss in the coming quartersQ3 2026
- Compliance with Nasdaq listing standardsnext 10-Q
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company was incorporated in 2022 as a holding company for operating companies in pharmaceuticals and healthcare services 1. Its portfolio includes Wellgistics LLC, an FDA-licensed wholesale distributor, Wellgistics Pharmacy, licensed in 32 states and the District of Columbia, and DelivMeds, a hub platform that transfers prescriptions to independent pharmacies 1. Effective July 22, 2026, the company changed its name to DataMeds AI and its Nasdaq symbol from WGRX to MEDS 2.
In the second quarter of 2026 the company describes a strategy of vertical integration across technology, pharmacy, pharmaceutical-adjacent products and telemedicine, with the 'Health Lives Here' app slated for launch in September 2026 together with NFL Alumni Health 3. A proposed transaction with Datavault AI, EOS Technology Holdings, Scilex Holdings and HealthBridge Advisors aims to consolidate intellectual property in blockchain, biometrics and pharmaceutical-adjacent products, and it has not yet closed 3.
Financially, the company reported revenue of 1.779 million USD in the second quarter of 2026, up 14% from the prior quarter, and a net operating loss of 18.363 million USD, driven mainly by debt extinguishment expenses and general and administrative costs 3. It raised 6.5 million USD in new funding in June 2026 and restructured 14.5 million USD of existing debt 3.
Segments
Wholesale distribution (Wellgistics LLC)
Wellgistics LLC is a federally licensed pharmaceutical wholesale distributor in all 50 states, serving independent pharmacies and small to mid-size manufacturers 1. Its portfolio is mainly topical generics with a dermatology focus, plus oral generics, brand products and over-the-counter items 1.
Pharmacy (Wellgistics Pharmacy)
Wellgistics Pharmacy provides general and specialty pharmacy services, including patient care coordination, compliance programs, financial assistance and REMS administration, and its revenue comes from payor reimbursement and patient copayments 1. The pharmacy was later rebranded Corexa Pharmacy under the Corexa Health umbrella 3.
Technology platform (DelivMeds)
DelivMeds is a hub platform that automates the prescription journey, from transfer to an in-network independent pharmacy through to related clinical services, and the company expects recurring SaaS transaction fees over time 1. The technology division has also developed EinsteinRx and PharmacyChain products for medical data analysis 3.
Market context
According to the Centers for Medicare & Medicaid Services, national health expenditure reached 4.5 trillion USD in 2022, or 17.3% of GDP, with the share expected to reach 19.7% by 2032 1. IQVIA reported that US medicine spending reached 435 billion USD in 2023, and specialty drugs, which are under 10% of drugs, account for over 50% of prescription drug spend 1.
The company targets a 'specialty lite' segment between specialty and general maintenance drugs, where weak medication adherence creates avoidable costs 1. Independent pharmacies, the company's core customers, are described as a network of over 19,000 pharmacies in the US 1.
Trends
- Rising healthcare spendingtailwind
A growing share of GDP devoted to health spending could support demand for distribution and pharmacy services if drug volumes keep rising 1.
- Pressure on reimbursementheadwind
Lower reimbursement levels from private or government payors could compress margins for pharmacies and distributors, a risk the company itself describes 1.
- Interest in digital care and GLP-1 therapiesmixed
Demand for adherence apps and telemedicine services could grow, and the company plans a service aimed at users of GLP-1 medications 3.
- Regulatory and listing requirementsheadwind
Healthcare regulation and the risk of Nasdaq delisting could constrain operations and financing, and the company carried out a reverse stock split partly to address this risk 3.
Competitive position
The company operates in a market dominated by the three largest US wholesale distributors, and it seeks to complement rather than replace them by carrying products outside their portfolios 1. In digital hub and pharmacy services, competition is described as intense and constantly evolving 1.
The company names technology and data partners that are also potential competitors in certain services 23. Its joint venture with KareRx adds electronic benefits verification services, but this too depends on execution 3.
- The three largest US wholesale distributors
The companies the source identifies as the three largest wholesalers, which the company tries to complement with products outside their portfolios 1.
- Datavault AIDVLT
Partner in the proposed transaction, licensing patent-protected healthcare data tokenization 3.
- Scilex HoldingsSCLX
Source of patents the company intends to acquire for biometric confirmation of drug delivery 3.
- Cleveland Clinic
Institution that completed the first US drone delivery of medical products, without biometric confirmation 3.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This PointYahoo Finance — News · 18 Sept 2026 · EN
The latest news item in our archive is from 18 Sept 2026; the newest SEC filing is from 26 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report26 Oct 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report20 Oct 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report16 Oct 2026Material agreement · Delisting notice · Item 3.02
- Current report13 Oct 2026Other events
- Current report17 Sept 2026Other events
- Current report16 Sept 2026Material agreement · Creation of a direct financial obligation · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report18 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report17 Aug 2026
- Current report14 Aug 2026Other events · Financial statements and exhibits
- Current report04 Aug 2026Material agreement · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / DataMeds AI, Inc. · 20 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / DataMeds AI, Inc. · 17 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / DataMeds AI, Inc. · 18 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.